ch. 1. Progress in ovarian cancer research / Dilek Aktas -- ch. 2. Ovulation and ovarian surface epithelial cancer / William J. Murdoch and Anna C. McDonnel -- ch. 3. Ovarian sertoli-leydig cell tumors with heterologous elements / Evanthia Kostopoulou and Alexander Talerman -- ch. 4. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer / G. Hudelist ... [et al.] -- ch. 5. Role of membrane-associated serine/threonine phosphatase in ovarian cancer cell survival : evidence for minor role of apoptosis in gonadotropin-releasing hormone's antiproliferative signaling / Atsushi Imai ... [et al.] -- ch. 6. Docetaxel in combination with carboplatin as first-line chemotherapy for patients with epithelial ovarian cancer / Yoichi Aoki and Kenichi Tanaka -- ch. 7. Immunospecific albumin microspheres as delivery system for cisplatin and 5-fluorouracil for the treatment of ovarian adenocarcinoma / Ernest J. Truter and Aldina S. Santos -- ch. 8. Strategies for improving outcome in ovarian cancer : the role of surgery / Karsten Münstedt ... [et al.] -- ch. 9. Should systematic lymphadenectomy be performed in suboptimally debulked patients with stage III ovarian carcinoma? : a Degog study / Ugar Syagili ... [et al.] -- ch. 10. Outcomes for surgery in ovarian cancer / L. Elit -- ch. 11. Do ascites, mass volume and peritoneal carcinomatosis affect serum CA-125 levels in patients with ovarian carcinoma? : a different point of view / Ugar Saygili ... [et al.] -- ch. 12. The usefulness of serum CA-125 levels in the prediction of optimal primary cytoreduction in patients with advanced ovarian carcinoma / Ugar Syagili, Serkan Guclu and Oktay Erten -- ch. 13. Perceived risk of ovarian cancer, worry about ovarian cancer risk, and use of ovarian cancer screening by women at risk for ovarian cancer / M. Robyn Andersen ... [et al.] -- ch. 14. New strategy for the treatment of ovarian cancer with the aim to conquer chemoresistance / Junzo Kigawa ... [et al.] -- ch. 15. Treatment decision making in ovarian cancer / L. Elit.